Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Rituximab for non-Hodgkin's lymphoma: a story of rapid success in translation.

Harrison AM, Thalji NM, Greenberg AJ, Tapia CJ, Windebank AJ.

Clin Transl Sci. 2014 Feb;7(1):82-6. doi: 10.1111/cts.12111. Epub 2013 Oct 3.

2.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
3.

Rituximab faster infusion for patients with non-Hodgkin's lymphoma in the United States: implications for nursing practice.

Dawson K.

J Infus Nurs. 2013 May-Jun;36(3):172-8. doi: 10.1097/NAN.0b013e318288a103. Review.

PMID:
23558916
4.

Rituximab: how approval history is reflected by a corresponding patent filing strategy.

Storz U.

MAbs. 2014 Jul-Aug;6(4):820-37. doi: 10.4161/mabs.29105. Epub 2014 May 19. Review.

5.

Rituximab: an insider's historical perspective.

Grillo-López AJ.

Semin Oncol. 2000 Dec;27(6 Suppl 12):9-16.

PMID:
11226006
6.

Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.

Fanale MA, Younes A.

Drugs. 2007;67(3):333-50. Review.

PMID:
17335294
7.

Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials.

Griffin MM, Morley N.

Expert Opin Biol Ther. 2013 May;13(5):803-11. doi: 10.1517/14712598.2013.786698. Review.

PMID:
23560506
8.

Feasibility and toxicity of concomitant radio/immunotherapy with MabThera (Rituximab®) for patients with non-Hodkin's Lymphoma: results of a prospective phase I/II study.

Haidenberger A, Fromm-Haidenberger S, de Vries A, Popper BA, Steurer M, Skvortsova I, Kantner J, Gunsilius E, Lukas P.

Strahlenther Onkol. 2011 May;187(5):300-5. doi: 10.1007/s00066-011-2169-y. Epub 2011 Apr 26.

PMID:
21544528
9.

Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies.

Maloney DG, Press OW.

Oncology (Williston Park). 1998 Oct;12(10 Suppl 8):63-76. Review.

10.

Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.

Motta G, Cea M, Moran E, Carbone F, Augusti V, Patrone F, Nencioni A.

Clin Dev Immunol. 2010;2010:428253. doi: 10.1155/2010/428253. Epub 2011 Mar 6. Review.

11.

Antibody-targeted immunotherapy for treatment of non-Hodgkin's lymphoma.

White CA, Berlfein JR, Grillo-López AJ.

Curr Pharm Biotechnol. 2000 Dec;1(4):303-12. Review.

PMID:
11467328
12.

A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.

Molina A.

Annu Rev Med. 2008;59:237-50. doi: 10.1146/annurev.med.59.060906.220345. Review.

PMID:
18186705
13.

Rituximab immunotherapy for non-Hodgkin's lymphoma.

White CA.

Cancer Biother Radiopharm. 1999 Aug;14(4):241-50. Review.

PMID:
10850310
14.

Use of rituximab, the new FDA-approved antibody.

Leget GA, Czuczman MS.

Curr Opin Oncol. 1998 Nov;10(6):548-51. Review.

PMID:
9818234
15.

Current standards and future strategies in immunochemotherapy of non-Hodgkin's lymphoma.

Motta G, Cea M, Carbone F, Augusti V, Moran E, Patrone F, Nencioni A.

J BUON. 2011 Jan-Mar;16(1):9-15. Review.

PMID:
21674844
17.

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.

Piro LD, White CA, Grillo-López AJ, Janakiraman N, Saven A, Beck TM, Varns C, Shuey S, Czuczman M, Lynch JW, Kolitz JE, Jain V.

Ann Oncol. 1999 Jun;10(6):655-61.

18.

[Monoclonal antibody immunotherapy for malignant non-Hodgkin's lymphoma].

Jourdan E, Richard B.

Presse Med. 2000 Apr 8;29(13):717-21. French.

PMID:
10797826
19.

New developments in immunotherapy for non-Hodgkin's lymphoma.

Leonard JP, Furman RR, Ruan J, Coleman M.

Curr Oncol Rep. 2005 Sep;7(5):364-71. Review.

PMID:
16091197
20.

Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.

Dennie TW, Kolesar JM.

Clin Ther. 2009;31 Pt 2:2290-311. doi: 10.1016/j.clinthera.2009.11.031. Review.

PMID:
20110042
Items per page

Supplemental Content

Write to the Help Desk